With obesity and Type 2 diabetes on the rise, India is emerging as a key battleground for global drugmakers developing ...

COPENHAGEN - Danish drugmaker Novo Nordisk will launch its weight-loss drug Wegovy in India without any supply constraints, a ...

Wegovy, a weekly weight-loss injection by Novo Nordisk, has launched in India. Priced from Rs 17,000/month, it helps users lose up to 20 per cent body weight. But is it safe? Experts answer.

If the drug is more broadly used in people with obesity and not just diabetes, those with higher body weights may see even ...

Berger Montague investigates Hims and Hers after stock drops 26% following Novo Nordisk's termination of GLP-1 drug partnership.

A recent analysis of U.S. pharmacy claims reveals that nearly two-thirds of patients who initiated Wegovy or Zepbound in ...

Novo Nordisk NVO announced that it has ended its collaboration with telehealth provider Hims & Hers Health. In addition, the ...

Robert F. Kennedy Jr. testified in front of largely combative congresspeople on vaccine policy, his MAHA report and more; the ...

With the launch of Wegovy by Danish pharmaceutical giant Novo Nordisk and US major Eli Lilly’s Mounjaro already in ...

Wegovy is a GLP-1 receptor agonist that acts on key areas of the brain involved in appetite regulation and food intake ...

A unique business structure gives LifeMD access to the growing GLP-1 marketplace that can help boost the heavily shorted stock price. Read an analysis of LFMD here.